"Metabolic" is the largest category on most research catalogs and the least informative label on any of them. It groups a once-weekly incretin receptor agonist with a nucleoside that has to be phosphorylated inside the cell before it does anything, and files both next to a chimeric peptide that kills fat-cell vasculature outright. These compounds share a research question — energy balance and adiposity — and almost nothing else.
A more useful way to read the shelf is by where in the system a compound acts. Three broad places show up: the hormone receptors that report nutritional status to the brain, the intracellular machinery that senses and supplies cellular energy, and the fat cell itself. Sorting by that gives you a map. Sorting by the category label gives you a pile.
Tier one: the receptor layer, and the receptor-count ladder
The most clinically mature compounds in the category all act on class B G-protein-coupled receptors for gut and pancreatic hormones. They do not enter the cell or touch fat directly. They engage receptors that regulate insulin secretion, gastric emptying, glucagon tone and — importantly — hypothalamic appetite circuits.
Within this tier, the members differ mainly by how many receptors one molecule engages:
- Semaglutide — GLP-1 receptor mono-agonist
- Tirzepatide — dual GIP/GLP-1 receptor agonist
- Survodutide — dual GLP-1/glucagon receptor agonist
- Retatrutide — triple GIP/GLP-1/glucagon receptor agonist, in the Phase 3 TRIUMPH and TRANSCEND programs as of 2026
Adding glucagon receptor agonism is the notable design turn: glucagon was historically the hormone metabolic drugs tried to suppress, and its rehabilitation as an energy-expenditure and hepatic-fat lever is what separates survodutide and retatrutide from the GLP-1-only lineage. (You will see retatrutide marketed as a "GLP-3." There is no GLP-3 receptor. It is a marketing coinage, not pharmacology.)
Cagrilintide sits in this tier but on a separate axis. It is a long-acting amylin analog, and amylin receptors are not GLP-1 receptors at all — they are the calcitonin receptor (CTR) in complex with receptor activity-modifying proteins, with RAMP association shifting the receptor from calcitonin-preferring to amylin-preferring. Work published in eBioMedicine in 2025 pointed to AMY1 and AMY3 receptors in the brain as the ones cagrilintide's body-weight effect depends on, and a 2025 Nature Communications structural paper mapped its binding across calcitonin and amylin receptor complexes. An N-terminal C20 fatty acid gives it a roughly 7–8 day half-life. Because amylin and incretin signaling are genuinely different pathways, CagriSema exists as a co-formulation rather than a redundancy.
This tier is covered in depth elsewhere on the site — see the semaglutide vs. tirzepatide comparison for the receptor-selectivity and biased-agonism detail, and the incretin and amylin research roundup for the 2025–2026 trial readouts.
Tier two: inside the cell, where there is no receptor to hit
This is where the category stops being about hormones. Three catalog compounds act on intracellular energy sensing and cofactor supply — machinery that is normally tuned by exercise, fasting and substrate availability rather than by a circulating hormone binding a surface receptor.
The AMPK branch. AMP-activated protein kinase is the cell's fuel gauge: it activates when the AMP:ATP ratio rises, then switches on catabolic pathways and switches off anabolic ones.
MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial genome that has been studied as an endogenous regulator converging on AMPK — the basis for its "exercise mimetic" framing in the preclinical literature.
AICAR arrives at the same kinase by a completely different route, and it is worth being precise here: AICAR is not a peptide. It is a nucleoside that cells take up and adenosine kinase phosphorylates into ZMP, a nucleotide that structurally mimics AMP and allosterically activates AMPK. The prodrug step is the mechanism. Its research reputation rests largely on Narkar and colleagues' 2008 Cell work, in which sedentary mice given AICAR ran substantially longer than controls — the origin of the "exercise in a pill" phrase, and a rodent finding that has never been reproduced as a human performance result.
AICAR also carries the cleanest cautionary tale in the tier. Under the name acadesine, it was developed for cardioprotection during coronary artery bypass grafting, not for metabolism. The Phase 3 RED-CABG trial in roughly 3,000 surgical patients was stopped early at a prespecified futility analysis, with event rates essentially identical to placebo (Newman et al., JAMA 2012;308:157–164). And a systematic review in Cells (2021;10:1095) catalogued the compound's substantial AMPK-independent effects — meaning that when a paper reports an AICAR result, "AMPK activator" is a leaky label for what actually happened.
The cofactor branch. 5-Amino-1MQ is often shelved beside the above, but it is not an energy sensor compound at all. It is a small-molecule quinolinium — again, not a peptide — that inhibits nicotinamide N-methyltransferase (NNMT), the enzyme that consumes S-adenosylmethionine to methylate nicotinamide into 1-methylnicotinamide. NNMT is expressed at unusually high levels in adipose tissue, which is why fat is the tissue of interest.
Inhibiting that reaction is studied as a way to spare two currencies at once: the nicotinamide pool feeding NAD⁺ salvage, and the SAM methyl-donor budget. The primary work is Neelakantan and colleagues (Biochemical Pharmacology, 2018), which characterized membrane-permeable methylquinolinium NNMT inhibitors with reported selectivity over related methyltransferases, showed reduced intracellular 1-methylnicotinamide with raised NAD⁺ and SAM and suppressed lipogenesis in adipocytes, and reported reduced fat mass in diet-induced-obese mice without accompanying changes in food intake. That last detail is the mechanistically interesting one, because it distinguishes the proposed pathway from the appetite-mediated tier one story.
The honest summary of tier two: rich preclinical mechanism, thin or absent human efficacy data, and in AICAR's case a large completed trial that failed on its own endpoint. The NAD⁺ thread here overlaps with the longevity class primer, which covers the sirtuin side of the same cofactor.
Tier three: compounds aimed at the fat cell
Two catalog entries skip signaling entirely and target adipose tissue as the destination.
AOD-9604 and the unmodified HGH Fragment 176-191 — the latter filed under growth-hormone, pulled in here by mechanism rather than by shelf — derive from the C-terminal lipolytic domain of human growth hormone. They carry the sequence lineage of a growth-hormone fragment without the growth or IGF-1 activity; the proposed mechanism is adipocyte lipolysis and reduced lipogenesis, and it remains incompletely resolved at the receptor level. AOD-9604's distinguishing feature is a completed human program that missed: a Phase IIb weight-loss trial found no statistically significant separation from placebo, and development stopped in 2007.
Adipotide is the outlier in the whole category. It is not an agonist of anything. It is a chimeric peptide joining a homing sequence that binds prohibitin on white-adipose vasculature to a proapoptotic payload that is only toxic once internalized — a targeted cytotoxic, closer in design logic to oncology conjugates than to metabolic drugs. Its first-in-human trial was terminated with a small fraction of planned enrollment and no posted results. It was covered in full yesterday.
The category label is not a chemical class
Worth stating plainly, because it has practical consequences: of the compounds discussed above, AICAR is a nucleoside and 5-Amino-1MQ is a small-molecule quinolinium. Neither is a peptide. Neither has a sequence, a counterion story in the peptide sense, or a purity profile that reads like the ones on a peptide COA.
That matters when evaluating documentation. Reversed-phase HPLC and mass spectrometry mean different things for a small molecule than for a 39-residue lipidated peptide, and heavily lipidated incretin analogs behave differently on RP-HPLC than short unmodified peptides do. A certificate of analysis for a nucleoside is not evaluated by the same expectations as one for a synthesized peptide. See our quality documentation and the HPLC vs. mass spec explainer for what each method can and cannot establish.
Read the shelf by evidence maturity, not by adjacency
Sitting in the same catalog category implies nothing about how much is known. The gradient across this one is steeper than in any other class:
- Approved and outcome-tested — semaglutide, tirzepatide
- Phase 3, results accumulating — retatrutide, survodutide, cagrilintide/CagriSema
- Completed Phase 3, failed its endpoint — AICAR as acadesine, in a non-metabolic indication
- Completed Phase IIb, missed on efficacy — AOD-9604
- First-in-human trial terminated, no results posted — Adipotide
- Preclinical only — MOTS-c, 5-Amino-1MQ
Two compounds one row apart in a product grid can be separated by a decade of trials. That distance is the single most useful thing to know before reading any of the literature.
FAQ
Are all "metabolic" catalog compounds peptides? No. AICAR is a nucleoside and 5-Amino-1MQ is a small-molecule quinolinium. The category describes a research question, not a chemical class.
Why are amylin analogs grouped with incretins if the receptors differ? Because both act on the gut-brain hormone layer regulating appetite and gastric emptying. The receptors are genuinely distinct — amylin signals through calcitonin receptor/RAMP complexes — which is precisely why amylin and incretin agents have been investigated in combination rather than as substitutes.
Does a shared mechanism mean two compounds are interchangeable? No. MOTS-c and AICAR both converge on AMPK, but differ in chemistry, route to the target and pharmacokinetics. Mechanism identifies the pathway; it does not equate the molecules. Our pharmacokinetics primer covers why.
More background on individual compounds is available in the research library.
This article is educational and for the laboratory research community. Trulogic Labs products are sold for laboratory and research use only and are not for human consumption.